0


外源性致癌的昼夜节律控制与肿瘤药理学

Circadian control of xenobiotic carcinogenesis and cancer pharmacology
课程网址: http://videolectures.net/mdo2014_levi_circadian_control/  
主讲教师: Francis Lévi
开课单位: 华威大学
开课时间: 2014-07-21
课程语种: 英语
中文简介:
异源代谢和解毒,以及细胞周期事件、DNA修复、凋亡和血管生成都是由昼夜节律计时系统(CTS)有节奏地控制的,CTS是一个细胞时钟的层次和协调网络。涉及15个时钟基因的相互交织的转录/翻译反馈环有节奏地调节致癌外源物和抗癌药物的代谢和作用。解剖、生理或分子CTS破坏加速了癌症过程,包括实验模型中的起始、促进和进展,而CTS强化阻止了这些过程。这些实验数据支持CT在与轮班工作相关的癌症风险增加中的作用。时间疗法旨在通过根据昼夜节律提供药物来改善疗效。事实上,在实验模型和癌症患者中,昼夜节律可以改变抗癌药物耐受性的2到10倍。当药物接近其各自的最佳耐受性时,也可以看到疗效的改善。这些发现支持了特定于时间疗法的癌症治疗范式,即“毒性越小,疗效越好”(Lévi等人,Annu Rev Pharm Toxicol 2010)。虽然大多数时辰药理学效应已在明暗同步的哺乳动物中得到证实,但利用RNA干扰的时钟基因沉默技术,目前已在同步细胞培养中系统地研究了癌症时辰疗法的时钟稳健性和药物时间的相关性。最近的研究揭示了伊立替康生物活性、解毒、转运和分子靶相互作用的分子钟依赖性。它们进一步实现了细胞群体水平上chronoPK-PD关系的精确量化和数学建模(Dulong等人提交)。对小鼠和人类chronoPKPD的随机建模表明,最佳的时间疗法效果需要昼夜夹带在健康细胞中是稳定的,而在癌细胞中是微弱的,这一发现得到了实验数据的支持。此外,宿主的生物钟因性别和遗传背景不同而不同,并且可以随着剂量和昼夜节律的变化而被外源性物质进一步改变。我们发现,以伊立替康为模型,核心时钟基因Rev-Erbα和Bmal1的联合昼夜节律表达是不同品系和性别小鼠最佳用药时间的适当预测因子(Li et al.Cancer Res 2013)。目前的研究支持生理节律的相关性,该节律将两个时钟基因重置为临床相关CTS生物标记物,用于检测癌症风险和预测最佳时间治疗方案。
课程简介: Xenobiotic metabolism and detoxification, as well as cell cycle events, DNA repair, apoptosis and angiogenesis are rhythmically controlled by the Circadian Timing System (CTS), a hierarchical and coordinated network of cellular clocks. Interwoven transcription/translation feedback loops involving 15 clock genes rhythmically moderate metabolism and effects of carcinogenic xenobiotics and anticancer drugs. Anatomic, physiologic or molecular CTS disruption accelerates cancer processes, including initiation, promotion and progression in experimental models, while, CTS reinforcement halts these processes. These experimental data support a role for the CTS in the increased cancer risk associated to shift work. Chronotherapeutics aims at improving outcomes through the delivery of medicines according to circadian rhythms. Indeed, circadian timing can modify 2- to 10-fold the tolerability of anticancer medications in experimental models and in cancer patients. Improved efficacy is also seen when drugs are given near their respective times of best tolerability. These findings support a paradigm for cancer therapy that is specific to chronotherapy,i.e. "the lesser the toxicity, the better the efficacy" (Lévi et al. Annu Rev Pharm Toxicol 2010). While most chronopharmacologic effects have been shown in light-dark synchronized mammals, the relevance of clock robustness and drug timing for cancer chronotherapeutics is now systematically studied in synchronized cell cultures, using clock gene silencing with RNA interference. Recent studies reveal the molecular clock dependency of irinotecan bioactivation, detoxification, transport, and molecular target interactions. They further enable a precise quantification and mathematical modeling of chronoPK-PD relations at cell population levels (Dulong et al. submitted). Stochastic modeling of mouse and human chronoPKPD reveals that optimal chronotherapeutic effects require circadian entrainment to be robust in healthy cells and weak in cancer cells, a finding supported by experimental data. Moreover host clocks differ according to sex and genetic background, and can further be altered with xenobiotics as a function of dose and circadian timing. We find that the combined circadian expressions of core clock genes Rev- Erbα and Bmal1 are proper predictors of optimal drug timing in mice from different strains and sex, using irinotecan as a model (Li et al. Cancer Res 2013). Current studies support the relevance of the physiological rhythms that reset both clock genes as clinically relevant CTS biomarkers both for the detection of cancer risk and the prediction of optimal chronotherapeutics schedule.  
关 键 词: 昼夜节律计时系统; 癌症风险; 致癌外源物
课程来源: 视频讲座网
数据采集: 2021-12-24:zkj
最后编审: 2021-12-24:zkj
阅读次数: 67